ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD22
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD22
2
trial(s) found.
NCT07109219
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia (
ALLight
)
anti-CD22 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06788509
Advanced
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
+ bispecific T-cell engager,CD22-targeting
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (1)
Enrolling by invitation (1)
Recruitment Country and State
VIC (1)
NSW (1)
WA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Trial Type
Paed (1)
Advanced (1)
Cancer Therapy Class
CD22
100%
BTK
50%
CD20
50%
CD79b
50%
MALT1
50%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Lymphoid leukaemia
Castrate-resistant prostate cancer
Lymphoma
Male genital cancers
Myelodysplastic syndrome
Myeloproliferative neoplasm
Prostate adenocarcinoma
Prostate cancer
Solid tumour
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy